ID
42476
Description
Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. Please note that only cases with known outcome are collected! Baseline / diagnosis is defined as the day the sample of the first positive SARS-CoV-2 result was taken. Criteria of the Uncomplicated Phase: Asymptomatic OR Symptoms of upper respiratory tract infection and/or Nausea, emesis, diarrhea and/or Fever Remember: The Uncomplicated Phase ends, if a previously febrile patient has no fever anymore and has completed 14 days of follow-up without entering Complicated or Critical Phase; then move to Recovery Phase. Also, as soon as one of the criteria of the Complicated or Critical Phase are fulfilled, Uncomplicated Phase ends; move over to there. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Complicated Phase: * Need for oxygen supplementation (In patients with prior oxygen home therapy, clinically meaningful increase in need for oxygenation.) * paO2 at room air < 70 mmHg * SO2 at room air < 90 % * GOT or GPT > 5x ULN * New cardiac arrhythmia * New pericardial effusion >1cm * New heart failure with pulmonary edema, congestive hepatopathy or peripheral edema Remember: The Complicated Phase ends, if none of the criteria for the Complicated Phase is fulfilled anymore AND the patient is free of fever; then move to Recovery Phase. Also, as soon as one of the criteria of the Critical Phase are fulfilled, Complicated Phase ends; move over to Critical Phase. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Critical Phase: * Need for catecholamines * Life-threatening cardiac arrhythmia * Mechanical ventilation (invasive or non-invasive) * Liver failure with Quick< 50% * qSOFA >= 2 * Renal failure in need of dialysis Remember: The Critical Phase ends as soon as none of the criteria for the Critical Phase is fulfilled anymore AND the patient is free of fever. If the patient has died, it ends with the death of the patient. If the patient has died, do not report terminal values, i.e. those recorded after turning off life-support or heart rate "0" after death of the patient. Criteria of the Recovery Phase: *Improvement by at least one phase, i.e. Critical to Complicated or Complicated to Uncomplicated * Defervescence Remember: Uncomplicated asymptomatic patients enter recovery phase after 14 days of observation without disease progression No further progression or re-hospitalization If a text field can't be filled out, note 'ND' (for not determined).
Lien
Mots-clés
Versions (3)
- 02/07/2021 02/07/2021 - Sarah Riepenhausen
- 15/07/2021 15/07/2021 - Sarah Riepenhausen
- 16/07/2021 16/07/2021 - Sarah Riepenhausen
Détendeur de droits
LEOSS
Téléchargé le
16 juillet 2021
DOI
10.21961/mdm:42476
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients
Immunosuppressive premedication
- StudyEvent: Baseline
- StudyEvent: Comorbidities and Pre-medication
- StudyEvent: Phases
- StudyEvent: Therapeutics
- StudyEvent: Diagnostics
Description
Antibodies: CD-22
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C0054947
Description
Antibodies: CD-38
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C0075742
Description
Antibodies: CD-52
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C1610534
Description
Antibodies: Anti-CD79b
Alias
- UMLS CUI-1
- C0104979
- UMLS CUI-2
- C0003241
Description
Antibodies: B Lymphocyte stimulator-specific inhibitor (BLyS)
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C3160093
Description
Antibodies: CD19-BiTE
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C4727095
Description
Antibodies: Complement inhibitors
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C1564892
Description
Crovalimab
Type de données
integer
Alias
- UMLS CUI [1,1]
- C1564892
- UMLS CUI [1,2]
- C3846158
Description
Eculizumab
Type de données
integer
Alias
- UMLS CUI [1]
- C1541483
Description
Pegcetacoplan (APL-2)
Type de données
integer
Alias
- UMLS CUI [1]
- C4053680
Description
Ravulizumab
Type de données
integer
Alias
- UMLS CUI [1]
- C4550350
Description
Antibodies: Integrin antagonists
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C2917367
Description
Antibodies: Interleukin inhibitors
Alias
- UMLS CUI-1
- C3653320
- UMLS CUI-2
- C0003241
Description
Basiliximab
Type de données
integer
Alias
- UMLS CUI [1]
- C0676831
Description
Canakinumab
Type de données
integer
Alias
- UMLS CUI [1]
- C2718773
Description
Ixekizumab
Type de données
integer
Alias
- UMLS CUI [1]
- C3489764
Description
Sarilumab
Type de données
integer
Alias
- UMLS CUI [1]
- C3885145
Description
Secukinumab
Type de données
integer
Alias
- UMLS CUI [1]
- C3179547
Description
Tocilizumab
Type de données
integer
Alias
- UMLS CUI [1]
- C1609165
Description
Ustekinumab
Type de données
integer
Alias
- UMLS CUI [1]
- C1608841
Description
Antibodies: TNF-alpha inhibitors
Alias
- UMLS CUI-1
- C3653350
- UMLS CUI-2
- C0003241
Description
Adalimumab
Type de données
integer
Alias
- UMLS CUI [1]
- C1122087
Description
Certolizumab
Type de données
integer
Alias
- UMLS CUI [1]
- C1872109
Description
Etanercept
Type de données
integer
Alias
- UMLS CUI [1]
- C0717758
Description
Golimumab
Type de données
integer
Alias
- UMLS CUI [1]
- C2353893
Description
Infliximab
Type de données
integer
Alias
- UMLS CUI [1]
- C0666743
Description
Other Antibodies
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C0205394
Description
Inhibitors: Co-stimulation inhibitors
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C1622572
- UMLS CUI-3
- C1999216
Description
Inhibitors: Calcineurin inhibitors
Alias
- UMLS CUI-1
- C1562036
Description
Inhibitors: Interleukin inhibitor
Alias
- UMLS CUI-1
- C3653320
Description
Inhibitors: JAK inhibitors
Alias
- UMLS CUI-1
- C3854325
Description
Baricitinib
Type de données
integer
Alias
- UMLS CUI [1]
- C4044947
Description
Fedratinib
Type de données
integer
Alias
- UMLS CUI [1]
- C3886623
Description
Ruxolitinib
Type de données
integer
Alias
- UMLS CUI [1]
- C2931926
Description
Tofacitinib
Type de données
integer
Alias
- UMLS CUI [1]
- C2930696
Description
Upadacitinib
Type de données
integer
Alias
- UMLS CUI [1]
- C4726929
Description
Inhibitors: mTOR inhibitors
Alias
- UMLS CUI-1
- C2746052
Description
Inhibitor: PDE-4-inhibitor
Alias
- UMLS CUI-1
- C2936609
Description
Other Inhibitors
Alias
- UMLS CUI-1
- C0205394
- UMLS CUI-2
- C0243077
Description
Checkpoint inhibitors: last 3 months
Alias
- UMLS CUI-1
- C0332185
- UMLS CUI-2
- C4733472
Description
In case of combination therapy please indicate all of the respective drugs.
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C3657270
Description
In case of combination therapy please indicate all of the respective drugs.
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C3658706
Description
In case of combination therapy please indicate all of the respective drugs.
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C1367202
Description
In case of combination therapy please indicate all of the respective drugs.
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C4733472
Description
Indicate recent other checkpoint inhibitor
Type de données
text
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C4733472
- UMLS CUI [1,4]
- C1521902
Description
No recent checkpoint inhibitor therapy
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C1298908
- UMLS CUI [1,2]
- C0332185
- UMLS CUI [1,3]
- C4733472
Description
Unknown Checkpoint inhibitor therapy
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0439673
- UMLS CUI [1,2]
- C0332185
- UMLS CUI [1,3]
- C4733472
Description
Chemotherapeutics: Antimetabolites
Alias
- UMLS CUI-1
- C0003376
- UMLS CUI-2
- C0729502
Description
6-Mercaptopurine
Type de données
integer
Alias
- UMLS CUI [1]
- C0000618
Description
Azathioprine
Type de données
integer
Alias
- UMLS CUI [1]
- C0004482
Description
Leflunomide
Type de données
integer
Alias
- UMLS CUI [1]
- C0063041
Description
Methotrexate
Type de données
integer
Alias
- UMLS CUI [1]
- C0025677
Description
Mycophenolate mofetil / Mycophenolic acid
Type de données
integer
Alias
- UMLS CUI [1]
- C0209368
- UMLS CUI [2]
- C0026933
Description
Sulfasalazine
Type de données
integer
Alias
- UMLS CUI [1]
- C0036078
Description
Teriflunomide
Type de données
integer
Alias
- UMLS CUI [1]
- C1718383
Description
Chemotherapeutics: Cytostatics
Alias
- UMLS CUI-1
- C0010858
- UMLS CUI-2
- C0729502
Description
Recent: Cladribine (2-CDA) i.v./s.c.
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0092801
- UMLS CUI [1,2]
- C0348016
- UMLS CUI [1,3]
- C0332185
- UMLS CUI [2,1]
- C0092801
- UMLS CUI [2,2]
- C0021499
- UMLS CUI [2,3]
- C0332185
Description
Recent: Cladribine (2-CDA) p.o.
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0092801
- UMLS CUI [1,2]
- C0001563
- UMLS CUI [1,3]
- C0332185
Description
Recent: Cyclophosphamide i.v.
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0010583
- UMLS CUI [1,2]
- C0348016
- UMLS CUI [1,3]
- C0332185
Description
Recent: Cyclophosphamide p.o.
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0010583
- UMLS CUI [1,2]
- C0001563
- UMLS CUI [1,3]
- C0332185
Description
Recent: Mitoxantrone
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0026259
- UMLS CUI [1,2]
- C0332185
Description
Other Chemotherapeutics
Alias
- UMLS CUI-1
- C0205394
- UMLS CUI-2
- C0729502
Description
Other Chemotherapeutics
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0205394
- UMLS CUI [1,2]
- C0729502
Description
Indicate other Chemotherapeutics
Type de données
text
Alias
- UMLS CUI [1,1]
- C0729502
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C1521902
Description
Other immunosuppressive regimens: Corticosteroids
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0001617
Description
low dose prednisolone equivalent
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0445550
- UMLS CUI [1,2]
- C0038317
Description
medium dose prednisolone equivalent
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0439536
- UMLS CUI [1,2]
- C0178602
- UMLS CUI [1,3]
- C0038317
Description
high dose prednisolone equivalent
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0038317
- UMLS CUI [1,2]
- C0444956
Description
Other immunosuppressive regimens: Fumarate
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0220833
Description
Dimethyl fumarate
Type de données
integer
Alias
- UMLS CUI [1]
- C0058218
Description
Dimethyl fumarate/ethyl hydrogen fumarate (Fumaderm)
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0058218
- UMLS CUI [1,2]
- C0059764
- UMLS CUI [2]
- C0633802
Description
Other immunosuppressive regimens: Immunoglobulines
Alias
- UMLS CUI-1
- C1963758
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0021081
Description
Other immunosuppressive regimens: Interferon
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C3652465
Description
Other immunosuppressive regimens: Other Multiple Sclerosis drugs
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0013227
- UMLS CUI-4
- C0026769
Description
Other immunosuppressive regimens
Alias
- UMLS CUI-1
- C0205394
- UMLS CUI-2
- C0021081
Description
Other immunosuppressive drugs
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C0205394
Description
Indicate other immunosuppressive drugs
Type de données
text
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C1521902
Description
Immunosuppressive drugs: Underlying disease
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C3146298
Description
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0026769
Description
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0205494
- UMLS CUI [1,4]
- C0004364
- UMLS CUI [1,5]
- C0205394
Description
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0205478
Description
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0029216
Description
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C3495832
Description
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0277554
- UMLS CUI [1,4]
- C0205394
Description
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0277554
- UMLS CUI [1,4]
- C0205394
- UMLS CUI [1,5]
- C1521902
Description
Indication for immunosuppressive drugs: Unknown underlying disease
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0439673
- UMLS CUI [1,4]
- C0277554
Description
Is data entry for this section finished?
Alias
- UMLS CUI-1
- C4684556
- UMLS CUI-2
- C1828479
- UMLS CUI-3
- C0205197
Similar models
Immunosuppressive premedication
- StudyEvent: Baseline
- StudyEvent: Comorbidities and Pre-medication
- StudyEvent: Phases
- StudyEvent: Therapeutics
- StudyEvent: Diagnostics
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0003241 (UMLS CUI-2)
C3160093 (UMLS CUI-2)
C0332185 (UMLS CUI [1,2])
C1564892 (UMLS CUI-2)
C2917367 (UMLS CUI-2)
C0003241 (UMLS CUI-2)
C0003241 (UMLS CUI-2)
C1521902 (UMLS CUI [1,2])
C0003241 (UMLS CUI [1,3])
C1622572 (UMLS CUI-2)
C1999216 (UMLS CUI-3)
C1521902 (UMLS CUI [1,2])
C0243077 (UMLS CUI [1,3])
C4733472 (UMLS CUI-2)
C3657270 (UMLS CUI [1,2])
C3658706 (UMLS CUI [1,2])
C1367202 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C1521902 (UMLS CUI [1,4])
C0332185 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C0332185 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C0729502 (UMLS CUI-2)
C0026933 (UMLS CUI [2])
C0729502 (UMLS CUI-2)
C0348016 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0092801 (UMLS CUI [2,1])
C0021499 (UMLS CUI [2,2])
C0332185 (UMLS CUI [2,3])
C0001563 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0348016 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0001563 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0332185 (UMLS CUI [1,2])
C0729502 (UMLS CUI-2)
C0729502 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C1521902 (UMLS CUI [1,3])
C0205394 (UMLS CUI-2)
C0001617 (UMLS CUI-3)
C0038317 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,2])
C0038317 (UMLS CUI [1,3])
C0444956 (UMLS CUI [1,2])
C0205394 (UMLS CUI-2)
C0220833 (UMLS CUI-3)
C0059764 (UMLS CUI [1,2])
C0633802 (UMLS CUI [2])
C0205394 (UMLS CUI-2)
C0021081 (UMLS CUI-3)
C0348016 (UMLS CUI [1,2])
C0021499 (UMLS CUI [1,2])
C0205394 (UMLS CUI-2)
C3652465 (UMLS CUI-3)
C0205394 (UMLS CUI-2)
C0013227 (UMLS CUI-3)
C0026769 (UMLS CUI-4)
C0021081 (UMLS CUI-2)
C0205394 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C1521902 (UMLS CUI [1,3])
C3146298 (UMLS CUI-2)
C3146298 (UMLS CUI [1,2])
C0026769 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0205494 (UMLS CUI [1,3])
C0004364 (UMLS CUI [1,4])
C0205394 (UMLS CUI [1,5])
C3146298 (UMLS CUI [1,2])
C0205478 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0029216 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C3495832 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0277554 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,4])
C3146298 (UMLS CUI [1,2])
C0277554 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,4])
C1521902 (UMLS CUI [1,5])
C3146298 (UMLS CUI [1,2])
C0439673 (UMLS CUI [1,3])
C0277554 (UMLS CUI [1,4])
C1828479 (UMLS CUI-2)
C0205197 (UMLS CUI-3)
C1828479 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])